This review assessed the effects of short-term treatment with sedative hypnotics for insomnia in older people. The authors concluded that any treatment benefits were small and may not justify the increased risks in this population, particularly in those at risk of cognitive impairment or falls. This was a reasonably well-conducted review and the results appear reliable.
Data extraction
Two investigators independently extracted the data from the included studies; any disagreements were resolved by consensus.
Methods of synthesis
How were the studies combined? Cohen's d was used to estimate the effect size for measures of sleep quality. Pooled odds ratios (ORs) and their associated 95% confidence intervals (CIs) were obtained using random-effects meta-analyses for both measures of sleep quality and adverse events. The number-needed-to-treat (NNT) and number-needed-to-harm (NNH) were calculated for sleep quality and adverse events, respectively.
Funnel plots and Begg and Mazumar's rank correlation test were used to assess publication bias for all primary outcomes.
How were differences between studies investigated?
A chi-squared analysis was used to assess between-study differences for all combined results. A 'trim and fill' method was used to adjust for any heterogeneity found, and the results recalculated.
Results of the review
Twenty-four RCTs (n=2,511) were included in the review.
Quality of sleep.
The NNT for sedative hypnotics compared with placebo was calculated as 13 (95% CI: 6.7, 62.9), based on 4 studies.
Reported sleep quality was significantly better in participants who had received sedative hypnotics than in those who had received placebo; the mean effect size was 0.14 (95% CI: 0.05, 0.23), based on 8 studies. Compared with placebo, benzodiazepines were associated with a significant improvement in sleep quality; the mean effect size was 0.37 (95% CI: 0.01, 0.73), based on 7 studies. Heterogeneity was not reported. No statistically significant difference was found when zopiclone was compared with placebo; the mean effect size was 0.41 (95% CI: -0.76, 1.58), based on 2 studies. No statistically significant difference was found when benzodiazepine receptor agonists were compared with zaleplon, zopiclone and zolpidem (combined); the mean effect size was 0.04 (95% CI: -1.11, 1.19), based on 3 studies. The test for heterogeneity was not significant.
Sleep time.
Total sleep time was found to significantly improve in participants receiving any sedative compared with placebo; the mean increase in total sleep time was 25.2 minutes (95% CI: 12.8, 37.8), based on 8 studies. The test for heterogeneity was not significant. Compared with placebo, benzodiazepines significantly increased mean total sleep time by 34.2 minutes (95% CI: 16.2, 52.8), based on 8 studies. The test for heterogeneity was not significant. There were insufficient data available to analyse sleep onset latency or ease of going to sleep.
Number of awakenings.
Compared with placebo, the mean number of awakenings decreased significantly by 0.60 (6 studies; 95% CI: -0.41, -0.78) in participants receiving benzodiazepines. The test for heterogeneity was not significant.
Adverse events.
The NNH for sedative hypnotics compared with placebo was 6 (95% CI: 4.7, 7.1), based on all adverse events reported in 16 studies. The most common adverse events were drowsiness or fatigue, headache, nightmares, and nausea or gastrointestinal disturbances.
